We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Identifies Gestational Diabetes Risk in First Trimester

By LabMedica International staff writers
Posted on 29 Aug 2018
Print article
Image: The automated glycohemoglobin analyzer HLC-723G8 (G8) is used for diabetes monitoring and diagnosis (Photo courtesy of Tosoh Bioscience).
Image: The automated glycohemoglobin analyzer HLC-723G8 (G8) is used for diabetes monitoring and diagnosis (Photo courtesy of Tosoh Bioscience).
A blood test conducted as early as the 10th week of pregnancy may help identify women at risk for gestational diabetes, a pregnancy-related condition that poses potentially serious health risks for mothers and infants.

Gestational diabetes occurs only in pregnancy and results when the level of blood sugar, or glucose, rises too high. Gestational diabetes increases the mother's chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.

Scientists at the National Institute of Child Health and Human Development (NICHD, Bethesda, MD, USA) analyzed records from the NICHD Fetal Growth Study, a large observational study that recruited more than 2,000 low-risk pregnant women from 12 clinical sites in the USA between 2009 and 2013. The team compared HbA1c test results from 107 women who later developed gestational diabetes to test results from 214 women who did not develop the condition. Most of the women had tests at four intervals during pregnancy: early (weeks 8-13), middle (weeks 16-22 and 24-29) and late (weeks 34-37).

HbA1c was measured in an EDTA whole blood sample that was stored at <−70 °C and thawed immediately before analysis. HbA1c was measured using a non-porous ion Exchange High Performance Liquid Chromatography (HPLC) assay using the Tosoh Automated Analyzer HLC-723G8 (Tosoh Bioscience, Inc, South San Francisco, CA, USA). The assay coefficient of variation (CV) was less than 1.16%.

The investigators found that women who went on to develop gestational diabetes had higher HbA1c levels (an average of 5.3%), compared to those without gestational diabetes (an average HbA1c level of 5.1%). Each 0.1% increase in HbA1c above 5.1% in early pregnancy was associated with a 22% higher risk for gestational diabetes. In middle pregnancy, HbA1c levels declined for both groups. However, HbA1c levels increased in the final third of pregnancy, which is consistent with the decrease in sensitivity to insulin that often occurs during this time period.

Cuilin Zhang, PhD, an adjunct professor and the senior author of the study said, “Our results suggest that the HbA1C test potentially could help identify women at risk for gestational diabetes early in pregnancy, when lifestyle changes may be more effective in reducing their risk.” The study was published on August 16, 2018, in the journal Scientific Reports.

Related Links:
National Institute of Child Health and Human Development

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.